nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—PDE5A—clitoris—urinary bladder cancer	0.121	0.334	CbGeAlD
Pentoxifylline—PDE5A—penis—urinary bladder cancer	0.0343	0.0948	CbGeAlD
Pentoxifylline—Caffeine—ATM—urinary bladder cancer	0.0139	1	CrCbGaD
Pentoxifylline—NT5E—prostate gland—urinary bladder cancer	0.0126	0.0349	CbGeAlD
Pentoxifylline—ADORA2B—prostate gland—urinary bladder cancer	0.0108	0.0299	CbGeAlD
Pentoxifylline—CYP1A2—urine—urinary bladder cancer	0.00982	0.0272	CbGeAlD
Pentoxifylline—PDE4A—prostate gland—urinary bladder cancer	0.00963	0.0266	CbGeAlD
Pentoxifylline—NT5E—epithelium—urinary bladder cancer	0.00927	0.0256	CbGeAlD
Pentoxifylline—NT5E—smooth muscle tissue—urinary bladder cancer	0.00893	0.0247	CbGeAlD
Pentoxifylline—NT5E—renal system—urinary bladder cancer	0.0086	0.0238	CbGeAlD
Pentoxifylline—NT5E—urethra—urinary bladder cancer	0.00844	0.0234	CbGeAlD
Pentoxifylline—PDE5A—prostate gland—urinary bladder cancer	0.00818	0.0226	CbGeAlD
Pentoxifylline—ADORA2B—smooth muscle tissue—urinary bladder cancer	0.00765	0.0211	CbGeAlD
Pentoxifylline—ADORA2B—urethra—urinary bladder cancer	0.00723	0.02	CbGeAlD
Pentoxifylline—NT5E—female reproductive system—urinary bladder cancer	0.00688	0.019	CbGeAlD
Pentoxifylline—NT5E—vagina—urinary bladder cancer	0.00623	0.0172	CbGeAlD
Pentoxifylline—PDE5A—epithelium—urinary bladder cancer	0.00601	0.0166	CbGeAlD
Pentoxifylline—PDE5A—smooth muscle tissue—urinary bladder cancer	0.0058	0.016	CbGeAlD
Pentoxifylline—PDE4B—prostate gland—urinary bladder cancer	0.00574	0.0159	CbGeAlD
Pentoxifylline—PDE5A—renal system—urinary bladder cancer	0.00558	0.0154	CbGeAlD
Pentoxifylline—PDE5A—urethra—urinary bladder cancer	0.00548	0.0152	CbGeAlD
Pentoxifylline—ADORA2B—vagina—urinary bladder cancer	0.00533	0.0147	CbGeAlD
Pentoxifylline—ADORA1—renal system—urinary bladder cancer	0.00529	0.0146	CbGeAlD
Pentoxifylline—ADORA1—urethra—urinary bladder cancer	0.00519	0.0144	CbGeAlD
Pentoxifylline—ADORA2A—female reproductive system—urinary bladder cancer	0.00491	0.0136	CbGeAlD
Pentoxifylline—PDE5A—female reproductive system—urinary bladder cancer	0.00447	0.0124	CbGeAlD
Pentoxifylline—ADORA1—female reproductive system—urinary bladder cancer	0.00424	0.0117	CbGeAlD
Pentoxifylline—PDE5A—vagina—urinary bladder cancer	0.00404	0.0112	CbGeAlD
Pentoxifylline—NT5E—lymph node—urinary bladder cancer	0.00403	0.0111	CbGeAlD
Pentoxifylline—PDE4B—urethra—urinary bladder cancer	0.00384	0.0106	CbGeAlD
Pentoxifylline—ADORA1—vagina—urinary bladder cancer	0.00383	0.0106	CbGeAlD
Pentoxifylline—PDE4B—female reproductive system—urinary bladder cancer	0.00313	0.00866	CbGeAlD
Pentoxifylline—PDE4A—lymph node—urinary bladder cancer	0.00307	0.0085	CbGeAlD
Pentoxifylline—PDE4B—vagina—urinary bladder cancer	0.00283	0.00784	CbGeAlD
Pentoxifylline—PDE5A—lymph node—urinary bladder cancer	0.00261	0.00723	CbGeAlD
Pentoxifylline—ADORA1—lymph node—urinary bladder cancer	0.00248	0.00685	CbGeAlD
Pentoxifylline—CYP1A2—renal system—urinary bladder cancer	0.0024	0.00664	CbGeAlD
Pentoxifylline—PDE4B—lymph node—urinary bladder cancer	0.00183	0.00507	CbGeAlD
Pentoxifylline—Infestation—Methotrexate—urinary bladder cancer	0.000596	0.00144	CcSEcCtD
Pentoxifylline—Drowsiness—Methotrexate—urinary bladder cancer	0.000596	0.00144	CcSEcCtD
Pentoxifylline—Infestation NOS—Methotrexate—urinary bladder cancer	0.000596	0.00144	CcSEcCtD
Pentoxifylline—Pancytopenia—Epirubicin—urinary bladder cancer	0.000594	0.00143	CcSEcCtD
Pentoxifylline—Hypotension—Etoposide—urinary bladder cancer	0.000593	0.00143	CcSEcCtD
Pentoxifylline—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000588	0.00142	CcSEcCtD
Pentoxifylline—Dizziness—Thiotepa—urinary bladder cancer	0.000584	0.00141	CcSEcCtD
Pentoxifylline—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000583	0.00141	CcSEcCtD
Pentoxifylline—Urticaria—Fluorouracil—urinary bladder cancer	0.000581	0.0014	CcSEcCtD
Pentoxifylline—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00058	0.0014	CcSEcCtD
Pentoxifylline—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000578	0.00139	CcSEcCtD
Pentoxifylline—Sweating—Methotrexate—urinary bladder cancer	0.000572	0.00138	CcSEcCtD
Pentoxifylline—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000571	0.00138	CcSEcCtD
Pentoxifylline—Dyspnoea—Etoposide—urinary bladder cancer	0.000566	0.00137	CcSEcCtD
Pentoxifylline—Somnolence—Etoposide—urinary bladder cancer	0.000564	0.00136	CcSEcCtD
Pentoxifylline—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000564	0.00136	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000564	0.00136	CcSEcCtD
Pentoxifylline—Epistaxis—Methotrexate—urinary bladder cancer	0.000562	0.00136	CcSEcCtD
Pentoxifylline—Vomiting—Thiotepa—urinary bladder cancer	0.000562	0.00136	CcSEcCtD
Pentoxifylline—Infestation NOS—Epirubicin—urinary bladder cancer	0.000558	0.00135	CcSEcCtD
Pentoxifylline—Drowsiness—Epirubicin—urinary bladder cancer	0.000558	0.00135	CcSEcCtD
Pentoxifylline—Infestation—Epirubicin—urinary bladder cancer	0.000558	0.00135	CcSEcCtD
Pentoxifylline—Rash—Thiotepa—urinary bladder cancer	0.000557	0.00135	CcSEcCtD
Pentoxifylline—Dermatitis—Thiotepa—urinary bladder cancer	0.000557	0.00134	CcSEcCtD
Pentoxifylline—Headache—Thiotepa—urinary bladder cancer	0.000554	0.00134	CcSEcCtD
Pentoxifylline—Decreased appetite—Etoposide—urinary bladder cancer	0.000552	0.00133	CcSEcCtD
Pentoxifylline—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00055	0.00133	CcSEcCtD
Pentoxifylline—Body temperature increased—Cisplatin—urinary bladder cancer	0.000548	0.00132	CcSEcCtD
Pentoxifylline—Jaundice—Epirubicin—urinary bladder cancer	0.000544	0.00131	CcSEcCtD
Pentoxifylline—Constipation—Etoposide—urinary bladder cancer	0.000543	0.00131	CcSEcCtD
Pentoxifylline—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000542	0.00131	CcSEcCtD
Pentoxifylline—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000539	0.0013	CcSEcCtD
Pentoxifylline—Haemoglobin—Methotrexate—urinary bladder cancer	0.000538	0.0013	CcSEcCtD
Pentoxifylline—Haemorrhage—Methotrexate—urinary bladder cancer	0.000535	0.00129	CcSEcCtD
Pentoxifylline—Hepatitis—Methotrexate—urinary bladder cancer	0.000535	0.00129	CcSEcCtD
Pentoxifylline—Sweating—Epirubicin—urinary bladder cancer	0.000535	0.00129	CcSEcCtD
Pentoxifylline—Asthenia—Gemcitabine—urinary bladder cancer	0.000533	0.00129	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000528	0.00127	CcSEcCtD
Pentoxifylline—Epistaxis—Epirubicin—urinary bladder cancer	0.000526	0.00127	CcSEcCtD
Pentoxifylline—Pruritus—Gemcitabine—urinary bladder cancer	0.000526	0.00127	CcSEcCtD
Pentoxifylline—Nausea—Thiotepa—urinary bladder cancer	0.000525	0.00127	CcSEcCtD
Pentoxifylline—Feeling abnormal—Etoposide—urinary bladder cancer	0.000523	0.00126	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000519	0.00125	CcSEcCtD
Pentoxifylline—Pruritus—Fluorouracil—urinary bladder cancer	0.000517	0.00125	CcSEcCtD
Pentoxifylline—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000516	0.00125	CcSEcCtD
Pentoxifylline—Drowsiness—Doxorubicin—urinary bladder cancer	0.000516	0.00125	CcSEcCtD
Pentoxifylline—Infestation—Doxorubicin—urinary bladder cancer	0.000516	0.00125	CcSEcCtD
Pentoxifylline—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000511	0.00123	CcSEcCtD
Pentoxifylline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000509	0.00123	CcSEcCtD
Pentoxifylline—Urticaria—Etoposide—urinary bladder cancer	0.000504	0.00122	CcSEcCtD
Pentoxifylline—Haemoglobin—Epirubicin—urinary bladder cancer	0.000503	0.00122	CcSEcCtD
Pentoxifylline—Jaundice—Doxorubicin—urinary bladder cancer	0.000503	0.00121	CcSEcCtD
Pentoxifylline—Abdominal pain—Etoposide—urinary bladder cancer	0.000502	0.00121	CcSEcCtD
Pentoxifylline—Body temperature increased—Etoposide—urinary bladder cancer	0.000502	0.00121	CcSEcCtD
Pentoxifylline—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000502	0.00121	CcSEcCtD
Pentoxifylline—Hepatitis—Epirubicin—urinary bladder cancer	0.000501	0.00121	CcSEcCtD
Pentoxifylline—Haemorrhage—Epirubicin—urinary bladder cancer	0.000501	0.00121	CcSEcCtD
Pentoxifylline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.0005	0.00121	CcSEcCtD
Pentoxifylline—Asthenia—Cisplatin—urinary bladder cancer	0.000497	0.0012	CcSEcCtD
Pentoxifylline—Sweating—Doxorubicin—urinary bladder cancer	0.000495	0.00119	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000488	0.00118	CcSEcCtD
Pentoxifylline—Epistaxis—Doxorubicin—urinary bladder cancer	0.000487	0.00118	CcSEcCtD
Pentoxifylline—Immune system disorder—Methotrexate—urinary bladder cancer	0.000483	0.00117	CcSEcCtD
Pentoxifylline—Dizziness—Fluorouracil—urinary bladder cancer	0.000483	0.00117	CcSEcCtD
Pentoxifylline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000474	0.00114	CcSEcCtD
Pentoxifylline—Vomiting—Gemcitabine—urinary bladder cancer	0.000473	0.00114	CcSEcCtD
Pentoxifylline—Rash—Gemcitabine—urinary bladder cancer	0.000469	0.00113	CcSEcCtD
Pentoxifylline—Dermatitis—Gemcitabine—urinary bladder cancer	0.000468	0.00113	CcSEcCtD
Pentoxifylline—Hypersensitivity—Etoposide—urinary bladder cancer	0.000468	0.00113	CcSEcCtD
Pentoxifylline—Erythema—Methotrexate—urinary bladder cancer	0.000466	0.00112	CcSEcCtD
Pentoxifylline—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000466	0.00112	CcSEcCtD
Pentoxifylline—Headache—Gemcitabine—urinary bladder cancer	0.000466	0.00112	CcSEcCtD
Pentoxifylline—Flushing—Epirubicin—urinary bladder cancer	0.000465	0.00112	CcSEcCtD
Pentoxifylline—Vomiting—Fluorouracil—urinary bladder cancer	0.000465	0.00112	CcSEcCtD
Pentoxifylline—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000463	0.00112	CcSEcCtD
Pentoxifylline—Hepatitis—Doxorubicin—urinary bladder cancer	0.000463	0.00112	CcSEcCtD
Pentoxifylline—Rash—Fluorouracil—urinary bladder cancer	0.000461	0.00111	CcSEcCtD
Pentoxifylline—Dermatitis—Fluorouracil—urinary bladder cancer	0.00046	0.00111	CcSEcCtD
Pentoxifylline—Headache—Fluorouracil—urinary bladder cancer	0.000458	0.00111	CcSEcCtD
Pentoxifylline—Dysgeusia—Methotrexate—urinary bladder cancer	0.000456	0.0011	CcSEcCtD
Pentoxifylline—Asthenia—Etoposide—urinary bladder cancer	0.000456	0.0011	CcSEcCtD
Pentoxifylline—Immune system disorder—Epirubicin—urinary bladder cancer	0.000452	0.00109	CcSEcCtD
Pentoxifylline—Back pain—Methotrexate—urinary bladder cancer	0.000451	0.00109	CcSEcCtD
Pentoxifylline—Pruritus—Etoposide—urinary bladder cancer	0.000449	0.00108	CcSEcCtD
Pentoxifylline—Arrhythmia—Epirubicin—urinary bladder cancer	0.000447	0.00108	CcSEcCtD
Pentoxifylline—Nausea—Gemcitabine—urinary bladder cancer	0.000442	0.00107	CcSEcCtD
Pentoxifylline—Vomiting—Cisplatin—urinary bladder cancer	0.000441	0.00106	CcSEcCtD
Pentoxifylline—Vision blurred—Methotrexate—urinary bladder cancer	0.000439	0.00106	CcSEcCtD
Pentoxifylline—Rash—Cisplatin—urinary bladder cancer	0.000437	0.00105	CcSEcCtD
Pentoxifylline—Dermatitis—Cisplatin—urinary bladder cancer	0.000437	0.00105	CcSEcCtD
Pentoxifylline—Erythema—Epirubicin—urinary bladder cancer	0.000436	0.00105	CcSEcCtD
Pentoxifylline—Diarrhoea—Etoposide—urinary bladder cancer	0.000434	0.00105	CcSEcCtD
Pentoxifylline—Nausea—Fluorouracil—urinary bladder cancer	0.000434	0.00105	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000432	0.00104	CcSEcCtD
Pentoxifylline—Anaemia—Methotrexate—urinary bladder cancer	0.000431	0.00104	CcSEcCtD
Pentoxifylline—Flushing—Doxorubicin—urinary bladder cancer	0.00043	0.00104	CcSEcCtD
Pentoxifylline—Flatulence—Epirubicin—urinary bladder cancer	0.00043	0.00104	CcSEcCtD
Pentoxifylline—Tension—Epirubicin—urinary bladder cancer	0.000428	0.00103	CcSEcCtD
Pentoxifylline—Dysgeusia—Epirubicin—urinary bladder cancer	0.000427	0.00103	CcSEcCtD
Pentoxifylline—Nervousness—Epirubicin—urinary bladder cancer	0.000424	0.00102	CcSEcCtD
Pentoxifylline—Back pain—Epirubicin—urinary bladder cancer	0.000422	0.00102	CcSEcCtD
Pentoxifylline—Malaise—Methotrexate—urinary bladder cancer	0.00042	0.00101	CcSEcCtD
Pentoxifylline—Dizziness—Etoposide—urinary bladder cancer	0.00042	0.00101	CcSEcCtD
Pentoxifylline—Muscle spasms—Epirubicin—urinary bladder cancer	0.000419	0.00101	CcSEcCtD
Pentoxifylline—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000419	0.00101	CcSEcCtD
Pentoxifylline—Leukopenia—Methotrexate—urinary bladder cancer	0.000417	0.00101	CcSEcCtD
Pentoxifylline—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000414	0.000999	CcSEcCtD
Pentoxifylline—Nausea—Cisplatin—urinary bladder cancer	0.000412	0.000994	CcSEcCtD
Pentoxifylline—Vision blurred—Epirubicin—urinary bladder cancer	0.000411	0.000992	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000405	0.000977	CcSEcCtD
Pentoxifylline—Convulsion—Methotrexate—urinary bladder cancer	0.000404	0.000974	CcSEcCtD
Pentoxifylline—Vomiting—Etoposide—urinary bladder cancer	0.000404	0.000974	CcSEcCtD
Pentoxifylline—Erythema—Doxorubicin—urinary bladder cancer	0.000403	0.000974	CcSEcCtD
Pentoxifylline—Anaemia—Epirubicin—urinary bladder cancer	0.000403	0.000973	CcSEcCtD
Pentoxifylline—Agitation—Epirubicin—urinary bladder cancer	0.000401	0.000967	CcSEcCtD
Pentoxifylline—Rash—Etoposide—urinary bladder cancer	0.0004	0.000966	CcSEcCtD
Pentoxifylline—Dermatitis—Etoposide—urinary bladder cancer	0.0004	0.000965	CcSEcCtD
Pentoxifylline—Headache—Etoposide—urinary bladder cancer	0.000398	0.00096	CcSEcCtD
Pentoxifylline—Flatulence—Doxorubicin—urinary bladder cancer	0.000398	0.00096	CcSEcCtD
Pentoxifylline—Chest pain—Methotrexate—urinary bladder cancer	0.000397	0.000958	CcSEcCtD
Pentoxifylline—Myalgia—Methotrexate—urinary bladder cancer	0.000397	0.000958	CcSEcCtD
Pentoxifylline—Tension—Doxorubicin—urinary bladder cancer	0.000396	0.000956	CcSEcCtD
Pentoxifylline—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000395	0.000954	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000394	0.000951	CcSEcCtD
Pentoxifylline—Malaise—Epirubicin—urinary bladder cancer	0.000393	0.000949	CcSEcCtD
Pentoxifylline—Discomfort—Methotrexate—urinary bladder cancer	0.000392	0.000946	CcSEcCtD
Pentoxifylline—Nervousness—Doxorubicin—urinary bladder cancer	0.000392	0.000946	CcSEcCtD
Pentoxifylline—Leukopenia—Epirubicin—urinary bladder cancer	0.00039	0.000942	CcSEcCtD
Pentoxifylline—Back pain—Doxorubicin—urinary bladder cancer	0.00039	0.000942	CcSEcCtD
Pentoxifylline—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000388	0.000936	CcSEcCtD
Pentoxifylline—Palpitations—Epirubicin—urinary bladder cancer	0.000385	0.00093	CcSEcCtD
Pentoxifylline—Confusional state—Methotrexate—urinary bladder cancer	0.000383	0.000926	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00038	0.000918	CcSEcCtD
Pentoxifylline—Vision blurred—Doxorubicin—urinary bladder cancer	0.00038	0.000918	CcSEcCtD
Pentoxifylline—Convulsion—Epirubicin—urinary bladder cancer	0.000378	0.000912	CcSEcCtD
Pentoxifylline—Infection—Methotrexate—urinary bladder cancer	0.000378	0.000912	CcSEcCtD
Pentoxifylline—Nausea—Etoposide—urinary bladder cancer	0.000377	0.00091	CcSEcCtD
Pentoxifylline—Hypertension—Epirubicin—urinary bladder cancer	0.000376	0.000909	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000374	0.000904	CcSEcCtD
Pentoxifylline—Anaemia—Doxorubicin—urinary bladder cancer	0.000373	0.0009	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000372	0.000899	CcSEcCtD
Pentoxifylline—Chest pain—Epirubicin—urinary bladder cancer	0.000371	0.000896	CcSEcCtD
Pentoxifylline—Myalgia—Epirubicin—urinary bladder cancer	0.000371	0.000896	CcSEcCtD
Pentoxifylline—Agitation—Doxorubicin—urinary bladder cancer	0.000371	0.000895	CcSEcCtD
Pentoxifylline—Anxiety—Epirubicin—urinary bladder cancer	0.00037	0.000893	CcSEcCtD
Pentoxifylline—Skin disorder—Methotrexate—urinary bladder cancer	0.000369	0.000892	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000369	0.00089	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000368	0.000887	CcSEcCtD
Pentoxifylline—Discomfort—Epirubicin—urinary bladder cancer	0.000367	0.000885	CcSEcCtD
Pentoxifylline—Malaise—Doxorubicin—urinary bladder cancer	0.000364	0.000878	CcSEcCtD
Pentoxifylline—Dry mouth—Epirubicin—urinary bladder cancer	0.000363	0.000876	CcSEcCtD
Pentoxifylline—Anorexia—Methotrexate—urinary bladder cancer	0.000362	0.000875	CcSEcCtD
Pentoxifylline—Leukopenia—Doxorubicin—urinary bladder cancer	0.000361	0.000872	CcSEcCtD
Pentoxifylline—Confusional state—Epirubicin—urinary bladder cancer	0.000359	0.000866	CcSEcCtD
Pentoxifylline—Palpitations—Doxorubicin—urinary bladder cancer	0.000357	0.000861	CcSEcCtD
Pentoxifylline—Oedema—Epirubicin—urinary bladder cancer	0.000356	0.000859	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000356	0.000859	CcSEcCtD
Pentoxifylline—Hypotension—Methotrexate—urinary bladder cancer	0.000355	0.000858	CcSEcCtD
Pentoxifylline—Infection—Epirubicin—urinary bladder cancer	0.000354	0.000853	CcSEcCtD
Pentoxifylline—Shock—Epirubicin—urinary bladder cancer	0.00035	0.000845	CcSEcCtD
Pentoxifylline—Convulsion—Doxorubicin—urinary bladder cancer	0.00035	0.000844	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000348	0.000841	CcSEcCtD
Pentoxifylline—Hypertension—Doxorubicin—urinary bladder cancer	0.000348	0.000841	CcSEcCtD
Pentoxifylline—Tachycardia—Epirubicin—urinary bladder cancer	0.000347	0.000838	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000346	0.000836	CcSEcCtD
Pentoxifylline—Skin disorder—Epirubicin—urinary bladder cancer	0.000346	0.000834	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000344	0.00083	CcSEcCtD
Pentoxifylline—Insomnia—Methotrexate—urinary bladder cancer	0.000344	0.00083	CcSEcCtD
Pentoxifylline—Chest pain—Doxorubicin—urinary bladder cancer	0.000343	0.000829	CcSEcCtD
Pentoxifylline—Myalgia—Doxorubicin—urinary bladder cancer	0.000343	0.000829	CcSEcCtD
Pentoxifylline—Anxiety—Doxorubicin—urinary bladder cancer	0.000342	0.000826	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000341	0.000823	CcSEcCtD
Pentoxifylline—Discomfort—Doxorubicin—urinary bladder cancer	0.000339	0.000819	CcSEcCtD
Pentoxifylline—Anorexia—Epirubicin—urinary bladder cancer	0.000339	0.000819	CcSEcCtD
Pentoxifylline—Dyspnoea—Methotrexate—urinary bladder cancer	0.000339	0.000818	CcSEcCtD
Pentoxifylline—Somnolence—Methotrexate—urinary bladder cancer	0.000338	0.000816	CcSEcCtD
Pentoxifylline—Dry mouth—Doxorubicin—urinary bladder cancer	0.000336	0.000811	CcSEcCtD
Pentoxifylline—Dyspepsia—Methotrexate—urinary bladder cancer	0.000335	0.000808	CcSEcCtD
Pentoxifylline—Hypotension—Epirubicin—urinary bladder cancer	0.000333	0.000803	CcSEcCtD
Pentoxifylline—Confusional state—Doxorubicin—urinary bladder cancer	0.000332	0.000801	CcSEcCtD
Pentoxifylline—Decreased appetite—Methotrexate—urinary bladder cancer	0.000331	0.000798	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000329	0.000795	CcSEcCtD
Pentoxifylline—Oedema—Doxorubicin—urinary bladder cancer	0.000329	0.000795	CcSEcCtD
Pentoxifylline—Infection—Doxorubicin—urinary bladder cancer	0.000327	0.00079	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000324	0.000783	CcSEcCtD
Pentoxifylline—Shock—Doxorubicin—urinary bladder cancer	0.000324	0.000782	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000322	0.000778	CcSEcCtD
Pentoxifylline—Insomnia—Epirubicin—urinary bladder cancer	0.000322	0.000777	CcSEcCtD
Pentoxifylline—Tachycardia—Doxorubicin—urinary bladder cancer	0.000321	0.000776	CcSEcCtD
Pentoxifylline—Skin disorder—Doxorubicin—urinary bladder cancer	0.00032	0.000772	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000318	0.000768	CcSEcCtD
Pentoxifylline—Dyspnoea—Epirubicin—urinary bladder cancer	0.000317	0.000766	CcSEcCtD
Pentoxifylline—Somnolence—Epirubicin—urinary bladder cancer	0.000316	0.000764	CcSEcCtD
Pentoxifylline—Anorexia—Doxorubicin—urinary bladder cancer	0.000314	0.000758	CcSEcCtD
Pentoxifylline—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000313	0.000756	CcSEcCtD
Pentoxifylline—Dyspepsia—Epirubicin—urinary bladder cancer	0.000313	0.000756	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000311	0.000751	CcSEcCtD
Pentoxifylline—Decreased appetite—Epirubicin—urinary bladder cancer	0.000309	0.000747	CcSEcCtD
Pentoxifylline—Hypotension—Doxorubicin—urinary bladder cancer	0.000308	0.000743	CcSEcCtD
Pentoxifylline—Constipation—Epirubicin—urinary bladder cancer	0.000304	0.000735	CcSEcCtD
Pentoxifylline—Urticaria—Methotrexate—urinary bladder cancer	0.000302	0.000729	CcSEcCtD
Pentoxifylline—Body temperature increased—Methotrexate—urinary bladder cancer	0.000301	0.000726	CcSEcCtD
Pentoxifylline—Abdominal pain—Methotrexate—urinary bladder cancer	0.000301	0.000726	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.0003	0.000724	CcSEcCtD
Pentoxifylline—Insomnia—Doxorubicin—urinary bladder cancer	0.000298	0.000719	CcSEcCtD
Pentoxifylline—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000294	0.000709	CcSEcCtD
Pentoxifylline—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000293	0.000708	CcSEcCtD
Pentoxifylline—Somnolence—Doxorubicin—urinary bladder cancer	0.000293	0.000707	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000291	0.000702	CcSEcCtD
Pentoxifylline—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00029	0.0007	CcSEcCtD
Pentoxifylline—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000286	0.000691	CcSEcCtD
Pentoxifylline—Urticaria—Epirubicin—urinary bladder cancer	0.000283	0.000682	CcSEcCtD
Pentoxifylline—Constipation—Doxorubicin—urinary bladder cancer	0.000282	0.00068	CcSEcCtD
Pentoxifylline—Body temperature increased—Epirubicin—urinary bladder cancer	0.000281	0.000679	CcSEcCtD
Pentoxifylline—Abdominal pain—Epirubicin—urinary bladder cancer	0.000281	0.000679	CcSEcCtD
Pentoxifylline—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00028	0.000676	CcSEcCtD
Pentoxifylline—Asthenia—Methotrexate—urinary bladder cancer	0.000273	0.000659	CcSEcCtD
Pentoxifylline—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000271	0.000655	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000269	0.00065	CcSEcCtD
Pentoxifylline—Pruritus—Methotrexate—urinary bladder cancer	0.000269	0.000649	CcSEcCtD
Pentoxifylline—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000262	0.000633	CcSEcCtD
Pentoxifylline—Urticaria—Doxorubicin—urinary bladder cancer	0.000262	0.000631	CcSEcCtD
Pentoxifylline—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00026	0.000628	CcSEcCtD
Pentoxifylline—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00026	0.000628	CcSEcCtD
Pentoxifylline—Diarrhoea—Methotrexate—urinary bladder cancer	0.00026	0.000628	CcSEcCtD
Pentoxifylline—Asthenia—Epirubicin—urinary bladder cancer	0.000255	0.000616	CcSEcCtD
Pentoxifylline—Pruritus—Epirubicin—urinary bladder cancer	0.000252	0.000608	CcSEcCtD
Pentoxifylline—Dizziness—Methotrexate—urinary bladder cancer	0.000251	0.000607	CcSEcCtD
Pentoxifylline—Diarrhoea—Epirubicin—urinary bladder cancer	0.000243	0.000588	CcSEcCtD
Pentoxifylline—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000243	0.000586	CcSEcCtD
Pentoxifylline—Vomiting—Methotrexate—urinary bladder cancer	0.000242	0.000584	CcSEcCtD
Pentoxifylline—Rash—Methotrexate—urinary bladder cancer	0.00024	0.000579	CcSEcCtD
Pentoxifylline—Dermatitis—Methotrexate—urinary bladder cancer	0.00024	0.000578	CcSEcCtD
Pentoxifylline—Headache—Methotrexate—urinary bladder cancer	0.000238	0.000575	CcSEcCtD
Pentoxifylline—Asthenia—Doxorubicin—urinary bladder cancer	0.000236	0.00057	CcSEcCtD
Pentoxifylline—Dizziness—Epirubicin—urinary bladder cancer	0.000235	0.000568	CcSEcCtD
Pentoxifylline—Pruritus—Doxorubicin—urinary bladder cancer	0.000233	0.000562	CcSEcCtD
Pentoxifylline—Vomiting—Epirubicin—urinary bladder cancer	0.000226	0.000546	CcSEcCtD
Pentoxifylline—Nausea—Methotrexate—urinary bladder cancer	0.000226	0.000545	CcSEcCtD
Pentoxifylline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000225	0.000544	CcSEcCtD
Pentoxifylline—Rash—Epirubicin—urinary bladder cancer	0.000224	0.000542	CcSEcCtD
Pentoxifylline—Dermatitis—Epirubicin—urinary bladder cancer	0.000224	0.000541	CcSEcCtD
Pentoxifylline—Headache—Epirubicin—urinary bladder cancer	0.000223	0.000538	CcSEcCtD
Pentoxifylline—Dizziness—Doxorubicin—urinary bladder cancer	0.000218	0.000526	CcSEcCtD
Pentoxifylline—Nausea—Epirubicin—urinary bladder cancer	0.000211	0.00051	CcSEcCtD
Pentoxifylline—Vomiting—Doxorubicin—urinary bladder cancer	0.000209	0.000505	CcSEcCtD
Pentoxifylline—Rash—Doxorubicin—urinary bladder cancer	0.000208	0.000501	CcSEcCtD
Pentoxifylline—Dermatitis—Doxorubicin—urinary bladder cancer	0.000207	0.000501	CcSEcCtD
Pentoxifylline—Headache—Doxorubicin—urinary bladder cancer	0.000206	0.000498	CcSEcCtD
Pentoxifylline—ADORA2A—Circadian rythm related genes—EP300—urinary bladder cancer	0.000202	0.000959	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—GLI1—urinary bladder cancer	0.000199	0.000949	CbGpPWpGaD
Pentoxifylline—Nausea—Doxorubicin—urinary bladder cancer	0.000196	0.000472	CcSEcCtD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—urinary bladder cancer	0.000192	0.000914	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000191	0.00091	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000191	0.00091	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—ERBB2—urinary bladder cancer	0.000187	0.000889	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—TP53—urinary bladder cancer	0.000187	0.000889	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HDAC4—urinary bladder cancer	0.000186	0.000885	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000182	0.000866	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000182	0.000866	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—PPARG—urinary bladder cancer	0.00018	0.000855	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—KRAS—urinary bladder cancer	0.000177	0.000842	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000177	0.000842	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000177	0.000842	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—CREBBP—urinary bladder cancer	0.000173	0.000822	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—urinary bladder cancer	0.000168	0.000801	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000165	0.000784	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—RBX1—urinary bladder cancer	0.000163	0.000774	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000163	0.000774	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—CDKN1A—urinary bladder cancer	0.00016	0.00076	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—PTEN—urinary bladder cancer	0.000159	0.000758	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—urinary bladder cancer	0.000159	0.000757	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000159	0.000754	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000158	0.000751	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—TP53—urinary bladder cancer	0.000157	0.000748	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GLI1—urinary bladder cancer	0.000156	0.000742	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000155	0.000738	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000155	0.000738	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TSC1—urinary bladder cancer	0.000153	0.000728	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—HRAS—urinary bladder cancer	0.00015	0.000716	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—SRC—urinary bladder cancer	0.000148	0.000703	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—RBX1—urinary bladder cancer	0.000148	0.000703	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000148	0.000703	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000148	0.000703	CbGpPWpGaD
Pentoxifylline—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000147	0.0007	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000147	0.000697	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—JAG1—urinary bladder cancer	0.000146	0.000693	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000145	0.00069	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—TP53—urinary bladder cancer	0.000144	0.000686	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—PTGS2—urinary bladder cancer	0.000141	0.000673	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TSC1—urinary bladder cancer	0.000139	0.000661	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RBX1—urinary bladder cancer	0.000138	0.000658	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RBX1—urinary bladder cancer	0.000137	0.00065	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	0.000135	0.000643	CbGpPWpGaD
Pentoxifylline—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000135	0.000643	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000133	0.000634	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—JAG1—urinary bladder cancer	0.000132	0.000629	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TSC1—urinary bladder cancer	0.00013	0.000619	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—EGFR—urinary bladder cancer	0.00013	0.000616	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TSC1—urinary bladder cancer	0.000129	0.000612	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000126	0.000597	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000125	0.000593	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—JAG1—urinary bladder cancer	0.000124	0.000589	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—PTEN—urinary bladder cancer	0.000123	0.000587	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000123	0.000586	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—KRAS—urinary bladder cancer	0.000122	0.000582	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—JAG1—urinary bladder cancer	0.000122	0.000582	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—S100B—urinary bladder cancer	0.000118	0.000561	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—EP300—urinary bladder cancer	0.000118	0.00056	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—RHOA—urinary bladder cancer	0.000112	0.000532	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000112	0.000532	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000108	0.000514	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—S100B—urinary bladder cancer	0.000107	0.00051	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RBX1—urinary bladder cancer	0.000107	0.000508	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NCOR1—urinary bladder cancer	0.000106	0.000505	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000105	0.000498	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—HRAS—urinary bladder cancer	0.000104	0.000495	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000103	0.000492	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—IL2—urinary bladder cancer	0.000103	0.000491	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—RHOA—urinary bladder cancer	0.000102	0.000483	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TSC1—urinary bladder cancer	0.0001	0.000478	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—S100B—urinary bladder cancer	0.0001	0.000477	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—S100B—urinary bladder cancer	9.91e-05	0.000471	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CXCL8—urinary bladder cancer	9.82e-05	0.000467	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.81e-05	0.000467	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NCOR1—urinary bladder cancer	9.63e-05	0.000458	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—JAG1—urinary bladder cancer	9.56e-05	0.000455	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—RHOA—urinary bladder cancer	9.51e-05	0.000452	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—RHOA—urinary bladder cancer	9.39e-05	0.000447	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL2—urinary bladder cancer	9.38e-05	0.000446	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—IL2—urinary bladder cancer	9.38e-05	0.000446	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TERT—urinary bladder cancer	9.35e-05	0.000445	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.19e-05	0.000437	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.08e-05	0.000432	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NCOR1—urinary bladder cancer	9.02e-05	0.000429	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	9.01e-05	0.000429	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CXCL8—urinary bladder cancer	8.91e-05	0.000424	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NCOR1—urinary bladder cancer	8.91e-05	0.000424	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—IL2—urinary bladder cancer	8.78e-05	0.000418	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—IL2—urinary bladder cancer	8.68e-05	0.000413	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—FGFR3—urinary bladder cancer	8.58e-05	0.000408	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	8.54e-05	0.000406	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAT1—urinary bladder cancer	8.54e-05	0.000406	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL2—urinary bladder cancer	8.52e-05	0.000405	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TERT—urinary bladder cancer	8.49e-05	0.000404	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.4e-05	0.0004	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CXCL8—urinary bladder cancer	8.35e-05	0.000397	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—ESR1—urinary bladder cancer	8.33e-05	0.000396	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CXCL8—urinary bladder cancer	8.25e-05	0.000392	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	8.08e-05	0.000385	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL2—urinary bladder cancer	7.98e-05	0.000379	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TERT—urinary bladder cancer	7.95e-05	0.000378	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL2—urinary bladder cancer	7.88e-05	0.000375	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TERT—urinary bladder cancer	7.85e-05	0.000374	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	7.81e-05	0.000372	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—FGFR3—urinary bladder cancer	7.79e-05	0.000371	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—S100B—urinary bladder cancer	7.74e-05	0.000368	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ESR1—urinary bladder cancer	7.56e-05	0.00036	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—RHOA—urinary bladder cancer	7.34e-05	0.000349	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CREBBP—urinary bladder cancer	7.3e-05	0.000347	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—FGFR3—urinary bladder cancer	7.29e-05	0.000347	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IGF1—urinary bladder cancer	7.21e-05	0.000343	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—FGFR3—urinary bladder cancer	7.21e-05	0.000343	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—EGFR—urinary bladder cancer	7.17e-05	0.000341	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.1e-05	0.000338	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ESR1—urinary bladder cancer	7.08e-05	0.000337	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	7.03e-05	0.000335	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ESR1—urinary bladder cancer	7e-05	0.000333	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NCOR1—urinary bladder cancer	6.96e-05	0.000331	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—IL2—urinary bladder cancer	6.78e-05	0.000323	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—KRAS—urinary bladder cancer	6.78e-05	0.000322	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	6.64e-05	0.000316	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CREBBP—urinary bladder cancer	6.63e-05	0.000315	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—RHOA—urinary bladder cancer	6.6e-05	0.000314	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IGF1—urinary bladder cancer	6.55e-05	0.000311	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—EGFR—urinary bladder cancer	6.51e-05	0.00031	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	6.47e-05	0.000308	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	6.44e-05	0.000307	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CREBBP—urinary bladder cancer	6.21e-05	0.000295	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL2—urinary bladder cancer	6.16e-05	0.000293	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—KRAS—urinary bladder cancer	6.15e-05	0.000293	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TERT—urinary bladder cancer	6.14e-05	0.000292	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CREBBP—urinary bladder cancer	6.13e-05	0.000292	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IGF1—urinary bladder cancer	6.13e-05	0.000292	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—ERBB2—urinary bladder cancer	6.11e-05	0.000291	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—EGFR—urinary bladder cancer	6.1e-05	0.00029	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF1—urinary bladder cancer	6.06e-05	0.000288	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—EGFR—urinary bladder cancer	6.03e-05	0.000287	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—RHOA—urinary bladder cancer	6e-05	0.000285	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCL8—urinary bladder cancer	5.8e-05	0.000276	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—KRAS—urinary bladder cancer	5.76e-05	0.000274	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—HRAS—urinary bladder cancer	5.76e-05	0.000274	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—KRAS—urinary bladder cancer	5.69e-05	0.000271	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FGFR3—urinary bladder cancer	5.63e-05	0.000268	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RHOA—urinary bladder cancer	5.62e-05	0.000267	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ERBB2—urinary bladder cancer	5.55e-05	0.000264	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RHOA—urinary bladder cancer	5.55e-05	0.000264	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL2—urinary bladder cancer	5.54e-05	0.000264	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ESR1—urinary bladder cancer	5.47e-05	0.00026	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCND1—urinary bladder cancer	5.4e-05	0.000257	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL8—urinary bladder cancer	5.27e-05	0.00025	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—urinary bladder cancer	5.24e-05	0.00025	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—HRAS—urinary bladder cancer	5.23e-05	0.000249	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	5.23e-05	0.000249	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTEN—urinary bladder cancer	5.21e-05	0.000248	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ERBB2—urinary bladder cancer	5.2e-05	0.000247	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.19e-05	0.000247	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TYMP—urinary bladder cancer	5.17e-05	0.000246	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ERBB2—urinary bladder cancer	5.14e-05	0.000244	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL2—urinary bladder cancer	5.03e-05	0.000239	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EP300—urinary bladder cancer	4.97e-05	0.000237	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.97e-05	0.000236	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL8—urinary bladder cancer	4.93e-05	0.000235	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCND1—urinary bladder cancer	4.91e-05	0.000233	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—HRAS—urinary bladder cancer	4.9e-05	0.000233	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL8—urinary bladder cancer	4.87e-05	0.000232	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—HRAS—urinary bladder cancer	4.84e-05	0.00023	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SRC—urinary bladder cancer	4.84e-05	0.00023	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.79e-05	0.000228	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—urinary bladder cancer	4.76e-05	0.000227	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1A—urinary bladder cancer	4.75e-05	0.000226	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTEN—urinary bladder cancer	4.73e-05	0.000225	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—urinary bladder cancer	4.73e-05	0.000225	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL2—urinary bladder cancer	4.71e-05	0.000224	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—EGFR—urinary bladder cancer	4.71e-05	0.000224	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAT2—urinary bladder cancer	4.68e-05	0.000223	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL2—urinary bladder cancer	4.66e-05	0.000222	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCND1—urinary bladder cancer	4.59e-05	0.000219	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCND1—urinary bladder cancer	4.54e-05	0.000216	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EP300—urinary bladder cancer	4.52e-05	0.000215	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—urinary bladder cancer	4.46e-05	0.000212	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—KRAS—urinary bladder cancer	4.45e-05	0.000212	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.44e-05	0.000211	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTEN—urinary bladder cancer	4.43e-05	0.000211	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—urinary bladder cancer	4.41e-05	0.00021	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1A—urinary bladder cancer	4.39e-05	0.000209	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SRC—urinary bladder cancer	4.39e-05	0.000209	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTEN—urinary bladder cancer	4.38e-05	0.000208	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RHOA—urinary bladder cancer	4.34e-05	0.000206	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MYC—urinary bladder cancer	4.33e-05	0.000206	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EGFR—urinary bladder cancer	4.24e-05	0.000202	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EP300—urinary bladder cancer	4.23e-05	0.000201	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EP300—urinary bladder cancer	4.18e-05	0.000199	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SRC—urinary bladder cancer	4.11e-05	0.000196	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SRC—urinary bladder cancer	4.06e-05	0.000193	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.04e-05	0.000192	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ERBB2—urinary bladder cancer	4.01e-05	0.000191	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KRAS—urinary bladder cancer	4e-05	0.00019	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MYC—urinary bladder cancer	3.93e-05	0.000187	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EGFR—urinary bladder cancer	3.85e-05	0.000183	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.81e-05	0.000181	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.78e-05	0.00018	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.74e-05	0.000178	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.74e-05	0.000178	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.72e-05	0.000177	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MYC—urinary bladder cancer	3.68e-05	0.000175	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MYC—urinary bladder cancer	3.64e-05	0.000173	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL2—urinary bladder cancer	3.64e-05	0.000173	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KRAS—urinary bladder cancer	3.64e-05	0.000173	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.63e-05	0.000173	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EGFR—urinary bladder cancer	3.6e-05	0.000171	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.57e-05	0.00017	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGFR—urinary bladder cancer	3.56e-05	0.000169	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—urinary bladder cancer	3.56e-05	0.000169	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCND1—urinary bladder cancer	3.55e-05	0.000169	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—urinary bladder cancer	3.44e-05	0.000164	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.43e-05	0.000163	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTEN—urinary bladder cancer	3.42e-05	0.000163	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KRAS—urinary bladder cancer	3.4e-05	0.000162	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—HRAS—urinary bladder cancer	3.4e-05	0.000162	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KRAS—urinary bladder cancer	3.36e-05	0.00016	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EP300—urinary bladder cancer	3.26e-05	0.000155	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—urinary bladder cancer	3.23e-05	0.000154	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SRC—urinary bladder cancer	3.17e-05	0.000151	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—HRAS—urinary bladder cancer	3.09e-05	0.000147	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—urinary bladder cancer	3.03e-05	0.000144	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.01e-05	0.000143	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—urinary bladder cancer	2.99e-05	0.000142	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.93e-05	0.000139	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—HRAS—urinary bladder cancer	2.89e-05	0.000138	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—HRAS—urinary bladder cancer	2.86e-05	0.000136	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MYC—urinary bladder cancer	2.84e-05	0.000135	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.78e-05	0.000132	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.63e-05	0.000125	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.55e-05	0.000121	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.51e-05	0.00012	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.43e-05	0.000116	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.34e-05	0.000111	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—urinary bladder cancer	2.34e-05	0.000111	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.31e-05	0.00011	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.31e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HRAS—urinary bladder cancer	2.23e-05	0.000106	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.21e-05	0.000105	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.17e-05	0.000103	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.04e-05	9.72e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.66e-05	7.88e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.59e-05	7.57e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.3e-05	6.2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.14e-05	5.41e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.08e-05	5.15e-05	CbGpPWpGaD
